Radiopharm Theranostics

Forecast & Rating6 analysts currently cover Radiopharm Theranostics, with about 83.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $17.17, about 383.6% upside from the current price of $3.55. Price targets range from $12.99 to $30.17 — a wide spread, showing clear disagreement over just how much Radiopharm Theranostics can rise. For you, this means most professionals who study Radiopharm Theranostics closely still see room for the stock to rise. Data as of Jul 23, 2026; for reference only and not investment advice.